Request Trial
shutterstock_1106804450_penpics_studio
PENpics Studio / Shutterstock.com
5 August 2021GenericsSophie Topham

UK experimental use exemptions: Part 3—the expanded exemption

In the third article of a four-part series on experimental use exemptions from infringement in the UK, we consider the expansion of the original experimental use exemption (Section 60(5)(b) UK Patents Act [UKPA] 1977) introduced by the Legislative Reform (Patents) Order 2014/1997.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Teva wins Fed Circ appeal over J&J’s schizophrenia drug
2 April 2024   Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.
Generics
Bayer granted 10-day injunction in blood clot drug dispute
28 March 2024   Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.
Generics
‘March-in’ rights: Why Biden’s changes contradict the point of Bayh-Dole
18 February 2024   While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.


Editor's picks

SCOTUS shuts the door on Entresto ‘after-arising technology’ review
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

Editor's picks

Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

More features

Key EU and UK regulatory changes to watch for in 2026
UPC: A review of 2025 and what to expect in 2026
Mirum targets generics in quartet of suits over liver treatment
Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm
Regeneron v Alvotech: The big impact
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
Beyond traditional IP: A comprehensive AI strategy for life sciences
Teva scrubs 200-plus Orange Book patents after FTC turns the screw